FibroGen

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

FibroGen reports improved financials and readies for new therapy launches

FibroGen's financials improved in Q4 2022, with strong cash reserves.
Strategic focus on new therapy launches and pivotal Phase 3 data.
Progress in commercial manufacturing and readiness for potential launches.
Emphasis on FDA feedback for filing strategies and multiple efficacy endpoints.

FibroGen reports Q1 revenue growth, faces challenges in study results

FibroGen's Q1 2023 performance showed strong revenue but faced challenges with roxadustat's Phase 3 study results.
The company's strengths lie in commercial opportunities, financial stability, and adherence to rigorous data analysis methods.
Challenges include addressing study result concerns and uncertainties in funding tied to clinical milestones.
Opportunities exist in market expansion, especially in IPF treatment, and upcoming Phase 3 trials for pamrevlumab.

FibroGen reports revenue growth amidst challenges and promising opportunities

FibroGen's Q2 2023 performance showed revenue growth and cost reduction efforts.
The company faces challenges in pamrevlumab trials and patent validity issues in China.
However, opportunities lie in upcoming trial readouts and the early-stage oncology pipeline.
FibroGen's strategic pillars and commitment to cost savings are key strengths.

FibroGen reports robust Q3 earnings, eyes expansion amid market challenges

FibroGen's Q3 performance was strong, driven by revenue growth and promising trial results.
The company's strategic pillars and clear pricing strategies position it well for future growth.
While facing challenges like generic competition, FibroGen has opportunities for expansion and market differentiation.
Overall, FibroGen's financial health and pipeline developments indicate a positive outlook for the company.

FibroGen reports robust Q4 performance and eyes expansion opportunities

FibroGen's Q4 2023 earnings call showcased strong performance in China for roxadustat and provided a detailed financial update, addressing key inquiries from analysts.
The company's strategic pillars, emphasis on highest tolerable doses for efficacy, and promising Phase I results position FibroGen well for future growth and drug development.
While challenges exist in interpreting data and prioritizing studies, opportunities in expanding market reach, refining development strategies, and enhancing efficacy markers are evident.
Overall, FibroGen's proactive approach to addressing challenges and exploring opportunities underscores a commitment to innovation and growth in the pharmaceutical sector.

FibroGen reports robust earnings, eyes growth in China and oncology

FibroGen's Q1 2024 earnings call highlighted strong financial performance, promising drug developments, cost efficiencies, and strategic focus on future growth. Despite challenges like market competition and regulatory timelines, the company remains optimistic and proactive in pursuing opportunities for expansion.

FibroGen reports strong Q3 performance in China, eyes growth

FibroGen's Q3 2024 results reflect notable growth in Roxadustat sales in China, cost reductions, and improved financial performance, positioning the company for future success.
Despite facing challenges such as expense management and market uncertainties, FibroGen's strategic pillars, positive outlook, and cash reserves offer resilience and growth potential.
Opportunities lie in market expansion, innovation, and partnerships, signaling a promising trajectory for FibroGen to capitalize on its strengths and drive value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

A drug from San Francisco-based FibroGen Inc. (NASDAQ:FGEN) is one of five medications the Food and Drug Administration is expected to rule on in the next three months in what BioPharma Dive called "the most consequential quarter in the agency's history."

FDA Decision on FibroGen Drug Among Most Consequential

SAN FRANCISCO, Sept.  08, 2020  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of Percy Carter, MBA, PhD, to the newly-created position of Chief Scientific Officer, where he will lead FibroGen’s research efforts, leveraging more than 20 years of global biopharmaceutical leadership and experience.

FibroGen Appoints Percy Carter, MBA, PhD, as Chief Scientific Officer

SAN FRANCISCO, Aug.  11, 2020  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the initiation of LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab or placebo in combination with systemic corticosteroids in patients with non-ambulatory Duchenne muscular dystrophy (DMD).

FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy

FibroGen's (FGEN) CEO Enrique Conterno on Q2 2020 Results - Earnings Call Transcript

- Strong Second Quarter China Roxadustat Net Sales of $15.7 million -  - Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time -

FibroGen Reports Second Quarter 2020 Financial Results

- Appoints Aoife Brennan, M.B., B.Ch., President and CEO of Synlogic Inc. (NASDAQ:SYBX) -- Appoints Ben Cravatt, Ph.D., Professor and the Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute -

FibroGen Announces New Appointments to its Board of Directors

FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: FibroGen (FGEN) Q2 Earnings Expected to Decline

Everbridge

HubSpot

Inphi

Have you missed the rally of these 4 stocks in the past three years? HubSpot, Everbridge, FibroGen, and Inphi Corporation have grown more than 100% since the beginning of 2017 despite posting operating losses consistently in the past three years!

Building A Portfolio? Consider This Unconventional Stock Set

SAN FRANCISCO, July  23, 2020  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2020 financial results on Thursday, August 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.

FibroGen to Report Second Quarter 2020 Financial Results

FibroGen (FGEN) enrolls the first patient in a placebo-controlled phase II study on pamrevlumab in hospitalized patients with acute COVID-19 infection in the United States.

FibroGen Begins Phase II Study for Acute Coronavirus in US

SAN FRANCISCO, June  23, 2020  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the initiation of a randomized, double-blind, placebo-controlled Phase 2 Study investigating the efficacy and safety of pamrevlumab in hospitalized patients with acute coronavirus 2019 (COVID-19) infection. This multicenter trial is being conducted in the U.S. and will enroll approximately 130 patients with COVID-19.

FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19

SAN FRANCISCO, June  22, 2020  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of Thane Wettig to the newly-created position of Chief Commercial Officer, where he will lead FibroGen’s commercialization efforts, leveraging more than 30 years of global biopharmaceutical leadership and experience.

FibroGen Appoints Thane Wettig as Chief Commercial Officer

FibroGen (FGEN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

FibroGen (FGEN) in Focus: Stock Moves 6.5% Higher

FibroGen (FGEN) starts a phase II/III study in Italy on pamrevlumab versus standard of care in patients with severe COVID-19 infection.

FibroGen Initiates Phase II/III Study in Severe Coronavirus

SAN FRANCISCO, June  08, 2020  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) announced data from three roxadustat clinical trials, including the Phase 3 DOLOMITES study evaluating roxadustat for treatment of anemia in non-dialysis-dependent CKD patients compared to darbepoetin alfa, and ophthalmology findings from a Japan Phase 3 study evaluating roxadustat compared to darbepoetin alfa in patients on hemodialysis 1. These data were presented in virtual oral sessions of the 57th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Virtual Congress, taking place June 6 - 9, 2020. These trials were conducted by Astellas Pharma, Inc., FibroGen’s collaboration partner for roxadustat in Europe, Japan and certain other markets.

FibroGen Announces New Roxadustat Data Presented at 2020 ERA-EDTA Virtual Congress

Additional Pamrevlumab Clinical Trials Planned in Patients Hospitalized in United States with Severe COVID-19 Additional Pamrevlumab Clinical Trials Planned in Patients Hospitalized in United States with Severe COVID-19

FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in Italy with Severe COVID-19

Submission for the treatment of anemia in adult patients with chronic kidney disease Submission for the treatment of anemia in adult patients with chronic kidney disease

European Medicines Agency Accepts Astellas’ Marketing Authorization Application for Roxadustat

FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q1 2020 Results - Earnings Call Transcript

SAN FRANCISCO, May  08, 2020  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will participate in the Bank of America Securities 2020 Health Care Conference that is being held virtually on May 12-14, 2020. Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at 11:00 AM Eastern Time on Thursday, May 14. A live audio webcast will be available on the “Events & Presentations” section of the FibroGen website at www.fibrogen.com. A replay of the fireside chat will be available for 30 days.

FibroGen to Present at Bank of America Securities 2020 Health Care Conference

FibroGen (FGEN) delivered earnings and revenue surprises of -196.67% and -64.10%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

FibroGen (FGEN) Reports Q1 Loss, Lags Revenue Estimates

FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

SAN FRANCISCO, April  20, 2020  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the United Kingdom’s High Court of Justice has held certain patents1 relating to methods of using hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) to be invalid. This decision does not affect the validity of these patents across the rest of Europe.

FibroGen Reports UK Court Ruling

FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q4 2019 Results - Earnings Call Transcript

A decision on Roxadustat should arrive by Dec. 20.

FibroGen's Anemia Drug Goes to FDA for Review

The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.

News for FibroGen Stock (FGEN)